Epic Sciences is a biotechnology startup that operates in the cancer diagnostics market. The company offers a unique service known as Comprehensive Cancer Profiling. This service uses a multi-technology approach to analyze a single blood draw from a patient, providing valuable insights for clinicians and drug development professionals, particularly those focused on prostate and breast cancer.

The company's proprietary technology allows for the detection of circulating tumor cells (CTCs), cell-free tumor DNA (ctDNA), and immune cells in the blood. This information can help doctors understand the genetic makeup and behavior of cancer cells, which can guide treatment decisions. This is especially useful for patients with metastatic castration-resistant prostate cancer (mCRPC), a type of cancer that is difficult to treat.

Epic Sciences' AR-V7 test is the first of its kind to be reimbursed by Medicare. This test requires only a simple blood draw and can help patients and their doctors choose the most effective therapies.

In addition to serving patients and clinicians, Epic Sciences also partners with pharmaceutical and clinical investigation teams. The company's unbiased approach to cancer research helps these teams develop new drugs and understand how cancer grows and evolves.

Epic Sciences' business model is based on providing these diagnostic services to patients, clinicians, and pharmaceutical companies. The company makes money by charging for these services and through partnerships with other organizations in the healthcare sector.

Keywords: Biotechnology, Cancer Diagnostics, Comprehensive Cancer Profiling, Circulating Tumor Cells, Cell-Free Tumor DNA, Immune Cell Analysis, Metastatic Castration-Resistant Prostate Cancer, AR-V7 Test, Medicare Reimbursement, Pharmaceutical Partnerships.